STaMINA was a phase III trial comparing progression-free survival (PFS) among 758 pts randomized to:

  1. second autoHCT then lenalidomide (Len) maintenance 
  2. consolidation with Len/bortezomib/ dexamethasone (RVD) followed by Len maintenance
  3. Len maintenance

Long term outcomes are similar using ITT, but as treated analysis suggested a PFS benefit for tandem autoHCT, driven mainly by pts with high risk MM. Len discontinuation even at 38 mo was associated with inferior PFS.

Clinical trial information: NCT02322320

 

 

Previous Post
Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results
Next Post
Primary analysis of the randomized phase II trial of RVd with/without elotuzumab for newly diagnosed, high-risk multiple myeloma: SWOG-1211

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.